Role of RedoxEVs in Glioma/Glioma-Treatment Induced Cognitive Impairment

Grants and Contracts Details


High-grade glioma (HGG) is the most common primary brain cancer in adults. Glioma patients endure not only cancer but also a decline in cognitive function before and after cancer therapy, which severely impacts daily quality of life. While the problem of cognitive impairment (CI) is well recognized, our understanding of the underlying mechanism is far from complete. The underlying pathogenesis of CI is complex, and a growing body of evidence implicates pathological protein aggregates as mechanisms commonly involved in many of the hallmark features of cognition loss- related neurodegenerative diseases. HGG has a high level of reactive oxygen species (ROS), which generate the highly toxic lipid peroxidation product, 4-hydroxynonenal (HNE), leading to the inactivation of protein functions and to the accumulation of HNE-adducted protein aggregates. Our prior studies indicate that a primary ROS removal enzyme, manganese-containing superoxide dismutase (MnSOD), exhibits redox-active antioxidant (RAA) properties in protecting normal cells against ROS-mediated injury while enhancing radiation therapy of cancer cells. Our findings are consistent with recent reports showing that MnSOD mimetics exhibit RAA properties, serving as antioxidants in normal cells and prooxidants in cancer cells. In preliminary studies to elucidate the mechanistic underpinnings of CI in HGG, we found that MnSOD is adducted by HNE and accumulates in extracellular vesicles (RedoxEVs) released from the HGG cells and present in the serum of HGG patients that can cause the death of brain cells. We hypothesize that modulation of RedoxEV associated cytokines- and/or RedoxEVs-dependent prooxidant microenvironments in the brain with RAA, will reduce CI without reducing the efficacy of cancer therapeutics. We will test these novel hypotheses with two interrelated specific aims. Aim 1 will elucidate the mechanism and metabolism by which RedoxEVs induce neuronal injury. This aim will define the RedoxEVs-dependent mechanism and -dependent metabolism in glial cell activation and the role of cytokines-associated ROS in the fate of neurons. Aim 2 will determine the efficacy of RAAs in preventing HGG treatment-associated CI in neurons and preclinical models. This aim will substantiate our RedoxEV hypothesis using the MnSOD mimetic, BMX-001, which has been shown in clinical trials to be safe and also to extend the survival of HGG patients. This study uses state-of-the-art platforms including stable isotope-resolved metabolomics, a super resolution resonance scanner confocal microscopy with Imaris software, Seahorse instrument, and Oroboros O2K- Fluorometer. The expertise of the team, COBRE-CNS-Met unique resources, and our seminal studies provide an ideal experimental context to study the impact of RedoxEVs in terms of mechanistic and proof-of-concept studies associated with CI. The translational impact is the potential to provide quality of life care to cancer patients suffering from CI.
Effective start/end date10/23/232/29/24


  • National Institute of General Medical Sciences


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.